Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
M

Primary and Nodal Tumor Factors Warranting Postoperative Adjuvant Treatment and Timing of Therapy of Head&Neck Cancer

By Xth Eurasian Hematology-Oncology Congress FEATURING Musa Altun
By Xth Eurasian Hematology-Oncology Congress FEATURING Musa Altun
0 views
November 12, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
Head & Neck
13:20
Xth Eurasian Hematology-Oncology Congress

2019 Update on HPV+ Oropharyngeal Cancer: New 8th Edition Staging Gi…

Feat. K. Toraman
13:48
Xth Eurasian Hematology-Oncology Congress

New 8th Edition Staging in HPV+ Oropharyngeal Cancer: De-Escalation …

Feat. K. Toraman
32:46
Xth Eurasian Hematology-Oncology Congress

Surgical Options for p16-Negative Advanced Head and Neck Cancer

Feat. B. Basaran
12:53
Xth Eurasian Hematology-Oncology Congress

Primary and Nodal Tumor Factors Warranting Postoperative Adjuvant Tr…

Feat. M. Altun
08:59
Xth Eurasian Hematology-Oncology Congress

Postoperative Adjuvant Therapy Options in Head&Neck Cancer: Conc…

Feat. M. Altun